NURIX THERAPEUTICS, INC. (NRIX) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-05-31..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-05-31..
Cash and securities
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 67.69M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-05-31 | (m) | (m) | $67.69M | (m) | (m) |
| 2026-02-28 | (m) | (m) | $71.19M | (m) | (m) |
| 2025-11-30 | (m) | (m) | $246.96M | (m) | (m) |
| 2025-08-31 | (m) | (m) | $78.44M | (m) | (m) |
| 2025-05-31 | (m) | (m) | $84.26M | (m) | (m) |
| 2025-02-28 | (m) | (m) | $75.92M | (m) | (m) |
| 2024-11-30 | (m) | (m) | $110.00M | (m) | (m) |
| 2024-08-31 | (m) | (m) | $99.04M | (m) | (m) |
| 2024-05-31 | (m) | (m) | $116.79M | (m) | (m) |
| 2024-02-29 | (m) | (m) | $49.81M | (m) | (m) |
| 2023-11-30 | (m) | (m) | $54.63M | (m) | (m) |
| 2023-08-31 | $258.85M | (m) | $42.30M | $216.55M | (m) |
| 2023-05-31 | $281.18M | (m) | $58.96M | $222.22M | (m) |
| 2023-02-28 | $277.15M | (m) | $33.57M | $243.57M | (m) |
| 2022-11-30 | (m) | (m) | $64.47M | (m) | (m) |
| 2022-08-31 | $344.48M | (m) | $47.56M | $296.92M | (m) |
| 2022-05-31 | (m) | (m) | $41.53M | (m) | (m) |
| 2022-02-28 | (m) | (m) | $78.78M | (m) | (m) |
| 2021-11-30 | (m) | (m) | $80.51M | (m) | (m) |
| 2021-08-31 | (m) | (m) | $147.44M | (m) | (m) |
| 2021-05-31 | (m) | (m) | $188.21M | (m) | (m) |
| 2021-02-28 | (m) | (m) | $126.38M | (m) | (m) |
| 2020-11-30 | (m) | (m) | $119.36M | (m) | (m) |
| 2020-08-31 | (m) | (m) | $265.53M | (m) | (m) |
| 2019-11-30 | (m) | (m) | $34.82M | (m) | (m) |
| 2019-08-31 | (m) | (m) | $51.85M | (m) | (m) |
| 2018-11-30 | (m) | (m) | $25.59M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |